Published in Lancet on August 31, 2008
Limus Eluted From A Durable Versus ERodable Stent Coating (LEADERS) | NCT00389220
BES, EES, and ZES-R in Real World Practice (CHOICE) | NCT01397175
e-NOBORI Observational Registry of Nobori DES (e-NOBORI) | NCT01261273
Bioresorbable scaffolds for percutaneous coronary interventions. Glob Cardiol Sci Pract (2014) 1.01
Assessment of in-stent restenosis using 64-MDCT: analysis of the CORE-64 Multicenter International Trial. AJR Am J Roentgenol (2010) 0.93
Second- and third-generation drug-eluting coronary stents: progress and safety. Herz (2011) 0.93
High-definition computed tomography for coronary artery stent imaging: a phantom study. Korean J Radiol (2011) 0.91
Optical coherence tomography: from research to practice. Eur Heart J Cardiovasc Imaging (2012) 0.90
Bioresorbable scaffolds in the treatment of coronary artery disease. Med Devices (Auckl) (2013) 0.90
New drug-eluting stent concepts. Nat Rev Cardiol (2010) 0.89
Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol (2011) 0.88
Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics (2014) 0.87
New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol (2013) 0.87
Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.85
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84
Vascular restoration therapy and bioresorbable vascular scaffold. Regen Biomater (2014) 0.84
Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol (2011) 0.84
The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer. J Cardiovasc Thorac Res (2011) 0.82
External validity of the "all-comers" design: insights from the BIOSCIENCE trial. Clin Res Cardiol (2016) 0.81
Percutaneous coronary intervention in patients with diabetes: current concepts and future directions. J Diabetes Sci Technol (2014) 0.81
Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol (2012) 0.80
Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STEnt IN patients with coronary artery disease) Registry. Einstein (Sao Paulo) (2013) 0.80
Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. PLoS One (2013) 0.80
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. Biologics (2013) 0.79
The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study. Eur J Clin Pharmacol (2010) 0.79
Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol (2013) 0.78
One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India. Indian Heart J (2013) 0.78
Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching. Yonsei Med J (2017) 0.78
Four-year clinical follow-up of the first-in-man randomized comparison of a novel sirolimus eluting stent with abluminal biodegradable polymer and ultra-thin strut cobalt-chromium alloy: the INSPIRON-I trial. Cardiovasc Diagn Ther (2015) 0.78
Efficacy and safety of a biodegradable polymer sirolimus-eluting stent in primary percutaneous coronary intervention: a randomized controlled trial. Arch Med Sci (2013) 0.77
Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. Eur J Med Res (2015) 0.77
Advances in stent technologies and their effect on clinical efficacy and safety. Med Devices (Auckl) (2014) 0.77
Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery. Int J Nanomedicine (2014) 0.77
Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography. Int J Cardiovasc Imaging (2013) 0.76
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. J Am Heart Assoc (2016) 0.75
Risk stratification for ST segment elevation myocardial infarction in the era of primary percutaneous coronary intervention. World J Cardiol (2014) 0.75
Choice of DES: is there a difference? Heart Asia (2009) 0.75
Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis. BMC Cardiovasc Disord (2015) 0.75
One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. J Tehran Heart Cent (2016) 0.75
Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers. Med Devices (Auckl) (2009) 0.75
The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents. PLoS One (2014) 0.75
Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study. J Interv Cardiol (2013) 0.75
Drug-eluting stents: is new necessarily better? Lancet (2008) 0.75
Controversies in the use & implementation of drug-eluting stent technology. Indian J Med Res (2012) 0.75
A prospective study evaluating efficacy of polymer free Pronova XR stent in treatment of denovo coronary artery stenosis. Indian Heart J (2014) 0.75
Coronary stent thrombosis: current insights into new drug-eluting stent designs. Chonnam Med J (2012) 0.75
Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study. Tex Heart Inst J (2016) 0.75
Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice. Cardiovasc Diagn Ther (2015) 0.75
A prospective, multi-centric, observational registry to evaluate performance of Excel™ DES in 'real world, all comers' patient population. Indian Heart J (2014) 0.75
Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up. Exp Ther Med (2015) 0.75
Percutaneous coronary intervention, a historical perspective looking to the future. J Thorac Dis (2013) 0.75
Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India. Indian Heart J (2013) 0.75
Optimal choice of coronary revascularization and stent type in diabetic patients with coronary artery disease. Cardiol Ther (2013) 0.75
Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. Indian Heart J (2014) 0.75
Interventional cardiology: A new drug-eluting stent that does not live up to its promise. Nat Rev Cardiol (2009) 0.75
Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview. Indian Heart J (2013) 0.75
Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study). Yonsei Med J (2018) 0.75
Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent. J Mater Sci Mater Med (2017) 0.75
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med (2009) 13.42
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Universal definition of myocardial infarction. Circulation (2007) 11.69
Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med (2006) 11.66
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ (2002) 7.26
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med (2007) 6.17
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. N Engl J Med (2004) 5.76
Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ (2010) 5.68
Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med (2010) 5.43
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol (2013) 5.11
Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94
Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med (2012) 4.87
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J (2006) 4.69
High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med (2015) 4.68
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imaging. J Am Coll Cardiol (2006) 4.37
Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med (2014) 4.37
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol (2005) 4.05
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol (2007) 3.82
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med (2015) 3.81
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60
All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ (2011) 3.51
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation (2007) 3.40
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. Eur Heart J (2010) 3.26
Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum (2007) 3.22
Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res (2005) 3.20
Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med (2002) 3.16
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med (2005) 3.08
Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol (2006) 3.07
Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06
Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation (2004) 3.02
Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01
Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation (2003) 2.97
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol (2005) 2.93